Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.
Saima Hassan MD, PhD, FRCSC
Advertisement
Articles by Saima Hassan MD, PhD, FRCSC
Saima Hassan, MD, PhD, FRCSC, discusses the rationale for examining talazoparib in combination with carboplatin in patients with triple-negative breast cancer.
Advertisement
Latest Updated Articles
Dr. Hassan on the Mechanism of Action of Talazoparib in TNBCPublished: May 12th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5